Trials / Completed
CompletedNCT02322229
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocriplasmin 0.125 mg in a 0.1 mL volume |
Timeline
- Start date
- 2015-05-26
- Primary completion
- 2015-12-11
- Completion
- 2016-05-09
- First posted
- 2014-12-23
- Last updated
- 2018-08-21
- Results posted
- 2018-07-23
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT02322229. Inclusion in this directory is not an endorsement.